(17α,20Z)-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17β-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (17α,20Z)-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17β-diol
• 英文别名: 17α-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17β-diol；(8R,9S,13S,14S,17R)-17-[(Z)-2-(4-aminophenyl)ethenyl]-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• 化学式: C₂₆H₃₁NO₂
• 分子量: 389.538
• InChiKey: KKNQKLOPVIXPBU-DAFMHTQJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  炔雌醇 在 四(三苯基膦)钯 吡啶 、 sodium hydroxide 、 三乙基硼 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 41.33h， 生成 (17α,20Z)-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17β-diol
  参考文献：
  名称：

  [EN] ESTRADIOL-RELATED COMPOUNDS AND METHODS OF USE AS ANTI-TUMOR AGENTS
  [FR] COMPOSES SE RAPPORTANT A L'OESTRADIOL, ET PROCEDES D'UTILISATION COMME AGENTS ANTITUMORAUX

  摘要：

  公开号：

  WO2005048956A3

文献信息

• Estradiol-related compounds and methods of use as anti-tumor agents
  申请人：Ho Shuk-Mei

  公开号：US20060025394A1

  公开（公告）日：2006-02-02

  This invention relates to new estradiol-related compounds that can be used to treat various types of cancer including prostate and breast cancers.

  本发明涉及可用于治疗包括前列腺癌和乳腺癌在内的各类癌症的新型雌二醇相关化合物。
• Synthesis and Evaluation of (17α,20<i>Z</i>)-21-(4-Substituted-phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as Ligands for the Estrogen Receptor-α Hormone Binding Domain:  Comparison with 20<i>E</i>-Isomers
  作者：Robert N. Hanson、Carolyn J. Friel、Robert Dilis、Alun Hughes、Eugene R. DeSombre

  DOI：10.1021/jm040157s

  日期：2005.6.1

  As part of our ongoing program to develop probes for the hormone binding domain of the estrogen receptor-alpha (ER alpha), we prepared and evaluated a series of 17 alpha,Z-(4-substituted-phenyl)-vinyl estradiol derivatives. The results indicated that the relative binding affinities (RBAs) at 25 degrees C for the new compounds were significant (RBA = 9-57) although less than that of estradiol (RBA = 100) or of the parent unsubstituted phenylvinyl estradiol (RBA = 66). All of the Z-compounds were full agonists in the uterotrophic assay, indicating that the ligands formed estrogen-like complexes with the estrogen receptor-alpha hormone binding domain (ER alpha-HBD). Comparison of corresponding Z- and E-4-substituted phenylvinyl ligands complexed with the ER alpha-HBD indicated small but significant differences in binding modes that may account for the differing trends seen in the structure-activity relationships for the two series.
• TRANSDERMAL DIETHYLSTILBESTROL FOR TREATING PROSTATE CANCER
  申请人：Beer Tomasz M.

  公开号：US20100016445A1

  公开（公告）日：2010-01-21

  Methods for treating prostate cancer comprising transdermally administering a therapeutically effective amount of diethylstilbesterol (DES), or a pharmaceutically acceptable salt or complex thereof, to a subject. In one embodiment, transdermally administered DES may be used to treat hot flashes in castrate prostate cancer patients. In another embodiment, transdermal DES may be administered as a therapy while avoiding testosterone surge and clinical tumor flare (for example, for treating symptomatic locally advanced prostate cancer, treating metastatic prostate cancer, or in a subject who is contraindicated for conventional therapy such as ADT therapy, particularly GnRH (gonadotropin-releasing hormone) therapy). In a further embodiment, transdermal DES may be administered to treat osteoporosis in men with prostate cancer. The transdermal DES may be used as a front line hormonal therapy or a second line hormonal therapy for treating prostate cancer.